 -- A gonist anti-CD40 mAb CDX-1140 demonstrates best-in-class potential; additional expansion cohorts initiated-- --Axl and CDX-527 programs highlighted-- HAMPTON, N.J., Nov. 09, 2020 GLOBE NEWSWIRE -- Celldex Therapeutics, Inc. NASDAQ:CLDX today announced data from multiple presentations at the Society for Immunotherapy of Cancers SITC 35th Anniversary Annual Meeting Pre-Conference Programs SITC 2020. An interim update from the Companys ongoing Phase 1 study of its CD40 agonist antibody, CDX-1140, and preclinical data from its AXL discovery program were presented at the meeting. In addition, the Phase 1 study design for the Companys bispecific candidate, CDX-527, which couples CD27 co-stimulation with blockade of the PD-L1PD-1 pathway, were also presented in a clinical trial in progress poster. 